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Nanocellulose hydrogel has been shown to be an excell nt platform for drug delivery and it has 23 
been lately studied as an injectable drug carrier. 3D printing is an effective method for fast 24 
prototyping of pharmaceutical devices with unique shape and cavities enabling new types of 25 
controlled release. In this study, we combined the versatility of 3D printing capsules with 26 
controlled geometry and the drug release properties of nanocellulose hydrogel to accurately 27 
modulate its drug release properties. We first manufact red non-active capsules via 3D printing 28 
from biocompatible poly(lactic acid) (PLA) that limt the direction of drug diffusion. As a novel 29 
method, the capsules were filled with a drug disperion composed of model compounds and 30 
anionic cellulose nanofiber (CNF) hydrogel. The main benefit of this device is that the release of 31 
any CNF-compatible drug can be modulated simply by modulating the inner geometry of the 32 
PLA capsule. In the study we optimized the size andshape of the capsules inner cavity and 33 
performed drug release tests with common beta blockers metoprolol and nadolol as the model 34 
compounds. The results demonstrate that the sustained release profiles provided by the CNF 35 
matrix can be accurately modulated via adjusting the geometry of the 3D printed PLA capsule, 36 
resulting in adjustable sustained release for the model compounds.  37 
 38 
Keywords: 3D printing, nanocellulose, hydrogel, sustained drug release  39 
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1 Introduction  40 
 41 
The increased access to 3D printers has accelerated the evelopment of new products and 42 
applications for drug release device development on the pharmaceutical field. These 43 
breakthroughs include 3D printing bilayers of different medicinal compounds into single oral 44 
dosage forms, oral tablets with inner channels and porous structures and adjustments on the 45 
geometry of printed oral capsules allowing customization of the drug release [1-5]. However, the 46 
usage of such geometrical innovations has not yet boomed on the rapidly growing market of 47 
implantable polymeric drug release devices [6]. These devices can be classified into four groups: 48 
passive polymeric implants, non-biodegradable polymeric implantable systems, biodegradable 49 
implants and dynamic or active implants [6]. In addition, the drug release mechanisms from such 50 
devices can be classified into four categories: controlled swelling, matrix degeneration, passive 51 
diffusion and osmotic pumping [7]. For implementation of drug release devices there are 52 
typically three main sites: subcutaneous, intra-vagin l and intra-vesical. [6] The usage of 53 
subcutaneous drug releasing devices is an invasive process and typically leaves permanent 54 
scarring. However, this can be the preferred treatmn  option when compared to continuous 55 
injections or daily pills or the drug implant has other benefits compared to oral dosing such as in 56 
the complex case of opioid addicted patients [8, 9]. 57 
 58 
Controlled swelling, passive diffusion and matrix degeneration have a key role in monolithic and 59 
reservoir type implants [6], which have been illustrated in Figure 1. In osmotic type implants, a 60 
non-permeating polymer is used and the osmotic gradient creates a stable inflow of body fluid 61 
within the device [10]. This increases the pressure inside the implant and forces drug release 62 
trough the opening as shown in Figure 1 [10]. Such design produces a constant drug release with 63 
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zero order kinetics [10]. Some monolithic implants feature no solid structures but instead rely on 64 
injectable drug releasing hydrogel formulations. Two recent interesting applications are a 65 
nanogel-based in situ forming implant for HIV drug release [11] and an application where CNF 66 
hydrogel formulations were subcutaneously injected in mice [12]. The injected CNF hydrogels 67 
operated as a monolithic type implant; the hydrogel had a high drug loading and the implant did 68 
not migrate or degrade despite the free movement of the mice [12]. In our work, we studied the 69 
use of a CNF hydrogel formulation as monolithic drug dispersions but inside a combination type 70 
implant illustrated in Figure 1. Successful clinical testing has been performed with a similar 71 
device, comprising of a simple cylindrical capsule fi led with a 2-hydroxyethyl methacrylate 72 
hydrogel and a therapeutic agent [13]. 73 
 74 
 75 




Cellulose-based nanostructured materials, generally known as a family of nanocelluloses, are 78 
interesting biocompatible materials, which have shown benefits in numerous medical 79 
applications [14]. Nanocellulose can be produced in three types: as bacterial cellulose (BC), 80 
cellulose nanocrystals (CNC) and as cellulose nanofibers (CNF) [15]. The cellulose nanofibers 81 
can be chemically modified by TEMPO [(2,2,6,6-tetramethylpiperidin-1-yl)oxyl] oxidation to 82 
manufacture anionic cellulose nanofibers [16, 19]. Lately, especially anionic CNF hydrogels 83 
have been shown to operate as a semi-universal drug matrix for the release of different types of 84 
molecules (small, large, cationic and anionic) [18, 9]. In addition, CNF has been used to 85 
manufacture drug-loaded film-like matrix systems with long-lasting sustained release for up to 86 
three months [20].  87 
 88 
Conventional 3D printing typically involves heat or ther manufacturing methods that limit its 89 
suitability for biomolecules, such as proteins and lipids [21]. The 3D printed drug delivery 90 
systems might further have an uneven or porous surface affecting the rate of the drug release, 91 
especially in extrusion and powder printing [22]. Extrusion, powder and inkjet-based printing 92 
require post-operative drying, which is an additional process variable affecting the appearance 93 
and the properties of the product [23]. However, it is possible to overcome these limitations by 94 
first printing customized capsules from an inert biocompatible material and then fill the capsules 95 
with sensitive drugs or biomolecules together with a release rate-controlling matrix material [24]. 96 
It is also possible to subsequently print a drug dosing cap to further enhance and modulate the 97 




In this study, we combine the new possibilities of printing specifically designed drug capsules 100 
and the recent advances in the implantation of CNF hydrogels into three rapid prototyped designs 101 
and evaluate their properties in vitro as sustained release devices. Traditionally in pharmaceutical 102 
hydrogel applications, the release rate of the drug is controlled by the concentration of the loaded 103 
drug and other active ingredients [25]. Here, a similar effect is expected by controlling the inner 104 
geometry of the capsule which limits drug diffusion from the hydrogel. The idea differs from the 105 
previously mentioned drug release devices and hydrogels as the release is fundamentally 106 
controlled by the inner hydrogel, which facilitates a sustained release profile while the release 107 
can be further modulated via the geometry of the inn r cavity of the capsule. 108 
  109 
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2 Materials and Methods  110 
 111 
2.1 Materials 112 
2.7% (lot 11724) anionic CNF hydrogel FibdexTM was purchased from UPM-Kymmene Oyj, 113 
Finland. PrimaValue™ poly(lactic acid) (PLA)  filaments were purchased from 3D Prima, 114 
Mälmö, Sweden. Nadolol, metoprolol tartrate and methyl ne blue, were purchased from Sigma-115 
Aldrich, USA. Dulbecco’s Phosphate Buffered Saline (10×) concentrate without calcium and 116 
magnesium was purchased from Gibco, UK. The buffer solution used was made in double 117 
distilled ultrapure water. 118 
2.2 Printing of PLA capsules 119 
The capsules were modeled with Onshape (Onshape inc, Cambridge, USA) Computer Aided 120 
Design (CAD) software and the CAD model was later processed with Slic3r -software package 121 
to produce the actual printing data. Capsules were printed from commercially available PLA 122 
filaments using fused deposition modeling (FDM) printing process. The FDM process is 123 
essentially an extrusion method where a heated material, in this case PLA, is directed through a 124 
nozzle and deposited in x, y and z space to to produce 3D constructs on the printing stage. In this 125 
study, the capsules were printed with 100% infill to ensure the sufficient barrier properties of the 126 
printed walls. 3D printing was carried out using PRUSA I3 MK2 (Prusa research, s.r.a., Praha, 127 
Czech republic) at 210 °C with a printing rate of 40 mm/s and 0.2 mm layer height. The printer 128 
nozzle diameter during the printing was 0.4 mm. No post processing, such as smoothing after the 129 
printing, was performed, however each capsule used in the experiments was hand-picked so that 130 
no visible unevenness around the release channel could be observed. The length of each 131 
produced capsule was 20 mm, and the width 10 mm. The diameter of the bottleneck was 2.0 mm 132 
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for small, 3.6 mm for large and 5.0 mm for tube design leading into shared constant flat surface 133 
areas of 3.1 mm2 for small, 10 mm2 for large and 19 mm2 for the tube design. The inner total 134 
volumes were 360 mm3 for the small, 430 mm3 for the large and 330 mm3 for the tube design. 135 
 136 
2.3 Leakage tests and injection of hydrogel formulations 137 
After the manufacturing of the capsules, leakage tests were performed using methylene blue as a 138 
dye for visual observation of possible leaks. First, a dyed hydrogel was made by mixing anionic 139 
CNF hydrogel with methylene blue and injecting it inside the capsules with standard 19G 140 
needles. The capsules were weighted before and after injection to ensure that a complete filling 141 
had been accomplished and to rule out the presence of air bubbles. Next, the capsules were wet 142 
and any leakage of the blue color trough the core was observed with a slow-motion camera.  143 
 144 
2.4. Preparation of the hydrogel formulations  145 
The hydrogel formulations were prepared by mixing anionic CNF hydrogel with the model 146 
compounds. The mixing was performed by connecting two 10 ml syringes from their nozzles 147 
with a tiny rubber hose and then pushing the contents of each syringe to the other via the hose. 148 
The anionic CNF hydrogel (fiber content 2.7%) was weighted directly in the syringes and 149 
nadolol or metoprolol was added as a dry powder. Nadolol and metoprolol were loaded in excess 150 
amount to form monolithic dispersions. The formulations were then homogenized by pushing the 151 
contents back and forth trough the hose for 5 min. The final amount of cellulose nanofibers in 152 
both formulations was 1.8 %. The total amount of metoprolol inside the capsules was 152 mg for 153 
the large design, 130 mg for the small design and 105 mg for the tube design. For nadolol, the 154 
amounts were 131 mg for the large capsule, 110 mg for the small design and 91 mg for the tube 155 
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design. The used quantity for nadolol represents concentration of 0.89 M. The solubility of 156 
nadolol in water is 0.03 M, meaning that the water-based hydrogel formulation can be 157 
characterized as a monolithic dispersion [26]. The solubility for metoprolol tartrate in water is 158 
much higher and therefore its solubility in the 2.7% ANFC hydrogel was tested separately with 159 
nephelometry. The results show that the hydrogel dos not possess enough free water to dilute all 160 
of the added metoprolol, resulting in a monolithic d spersion. The measured solubility data for 161 
metoprolol is shown in the supplementary data. 162 
 163 
2.5 In vitro drug release studies  164 
The 3D printed capsules were filled with formulated hydrogels via injection with standard 19G 165 
needles and the visible hydrogel surface was evened with plastic strips. The capsules were 166 
weighted before and after injection to ensure that a complete filling had been accomplished and 167 
to rule out the presence of air bubbles. The filled capsules were placed in glass bottles with 70 ml 168 
of phosphate buffered saline (1 x DPBS) and kept at 37 °C incubator shaker (Innova 4400, by 169 
ALLERGAN. Inc.) under constant shaking at 150 RPM for 3 weeks, except the small and large 170 
designs for nadolol were measured for 5 weeks. At chosen time points, 1 ml was collected from 171 
each sample and replaced with 1 ml of fresh buffer. The amount of removed model compound 172 
from each time point was mathematically added to the next time point in order to plot cumulative 173 
release. All experiments were performed in triplicate.  174 
 175 
2.6 Quantification of released model compounds  176 
The concentrations of nadolol and metoprolol from the in vitro release tests were analyzed with 177 
Ultra performance liquid chromatography (UPLC) instrument Acquity UPLC (Waters, USA). 178 
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For nadolol and metoprolol, the used column was HSS-T3 1.8 µm (2.1 × 50 mm) (Waters, USA) 179 
at 30 °C. The injection volume for nadolol was 5 µl and 2 µl for metoprolol and the flow rate was 180 
0.5 ml/min for both compounds. The detection of nadolol and metoprolol was performed at the 181 
wavelengths of 215 nm and 221 nm, respectively. During the gradient run the mobile phase 182 
consisted of a mixture of acetonitrile and 15 mM phosphate buffer at pH 2 in 10:90 ratio for 183 
nadolol and 20:80 for metoprolol. The retention times were 0.92 min for nadolol and 0.89 min 184 
for metoprolol. 185 
 186 
3 Results and Discussion  187 
We designed capsules that had an inner reservoir cav ty for the CNF hydrogel and a single 188 
release channel (to which we will be later referring as bottleneck). Outer measurements for each 189 
design were 10 mm x 20 mm and the capsules were 3D printed from PLA using fused deposition 190 
modelling (FDM) and filled with a suspension made of anionic CNF hydrogel and the model 191 
compounds, nadolol and metoprolol, which are both commonly used beta blockers. Nadolol’s 192 
release profile from anionic CNF hydrogels have been characterized previously, where 90% of 193 
the loaded nadolol diffused out of the hydrogel during one week [18]. PLA and anionic CNF 194 
hydrogel were chosen as materials for the capsules, as both are biocompatible materials (in 195 
humans) and biodegradable (in nature) [27-30].  196 
 197 
The designs of the manufactured capsules are visualized in Figure 2 (A-C) and with exact              198 
measurements in the supplementary material. The bottlenecks lead into inner cavities, which 199 
were filled with the anionic CNF hydrogel containing the studied model compound. We will 200 
refer to the different structures as small (Fig 2A), large (Fig 2B), and tube (Fig 2C) designs. The 201 
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designs presented here allow for a wide range of customization. As the PLA capsule carries and 202 
regulates the open surface area of the anionic CNF hydrogel, which operates as a matrix for the 203 
model compounds, the drug release can be controlled by modifying the characteristics of either 204 
component. However, as the release properties of ani nic CNF hydrogels have been established 205 
previously [18], we focused on the geometry of the PLA capsule and demonstrate that flexible 206 
control over the release rate can be achieved with minimal changes to the inner matrix. 207 
 208 
 209 
Fig 2.  Computer aided designs (A-C) and 3D printed versions (D-F) of the studied PLA 210 
capsules. (A) Small capsule. (B) Large capsule. (C) Tube design. (D) A 3D printed PLA capsule 211 
(small). (E-F) The large and tube designs filled with a hydrogel formulation after 3 weeks in 212 
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DPBS buffer still showing an even surface of the hydrogel. The image (F) has been taken with 213 
camera flash on to highlight the normally transparent anionic CNF hydrogel. 214 
 215 
3.1 Leakage tests and optimization of the PLA capsules 216 
The designs were first optimized not to leak via prototyping. Figure 2 shows the final optimized 217 
designs. We particularly had to optimize the bottom thickness as our first designs with a thin 218 
bottom leaked from the edges of the inner cavities. The combination of 3D printing and separate 219 
injection of the hydrogel allowed bypassing any requirements set by the FDM printing such as 220 
the required flow properties of the drugs [31]. The model compounds metoprolol and nadolol did 221 
not undergo any temperatures above 37 °C during the study, suggesting that the method would 222 
be compatible with biomolecules such as lipids and proteins. The final optimized designs are 223 
presented in Figure 2 A-C and with exact measurements in the supplementary data (Fig S1). 224 
 225 
3.2 Sustained in vitro release of the model compounds 226 
During the three-week release study, a sustained rel as  profile was obtained for both model 227 
compounds with all three PLA capsule designs. As expected, the small design with the smallest 228 
surface area in contact with the external buffer sustained the release the most for both model 229 
compounds. The large design had less effect on sustaining the release, and the tube design 230 
sustained the release the least. The results are shown in Figure 3, where the top three lines 231 
represent the release of the metoprolol filled PLA capsules, and the bottom three the nadolol 232 
filled PLA capsules. During the first hours all capsules released the model compounds rapidly 233 
and after the initial drug release the release rate w s observed as linear. For the tube design with 234 
metoprolol, the highest total release of 96.4% was reached on the 14th day. No swelling nor 235 
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collapsing of the hydrogels were visually observed during the three-week measurements, as 236 
shown in Figure 2 E still showing an even surface of hydrogel, matching the results of 237 
Paukkonen et al. [18]. After 14 days, the amount of metoprolol in the buffer appeared to decrease 238 
(data not shown). This is due to the hydrolysis of nadolol and metoprolol in aqueous conditions 239 
[32]. However, in the case of nadolol, this was not observable due to extremely sustained release, 240 
which allows a part of the drug dose to remain in crystallized form inside the hydrogel and hence 241 
delay the hydrolysis. As the hydrogels contained a significant amount of undissolved drug 242 
maintaining a constant reservoir system, the hydrogels can be characterized as monolithic 243 
dispersions. We performed solubility measurement for metoprolol in anionic CNF hydrogel with 244 
nephelometry and the results are shown in the supplementary data (Fig S2). 245 
 246 
 247 
Fig 3. Scaled cumulative release of the model compounds metoprolol (METO) and nadolol 248 
(NAD) from the three capsule designs (Tube, Large, and Small) carrying anionic cellulose 249 
nanofiber hydrogel drug formulations (mean ± S.D., n = 3). The experiments were conducted at 250 




3.2 Mathematical model for the release 253 
For monolithic dispersions with flat release areas, the release rate is expected to follow the 254 
Higuchi equation (1) [33]. 255 
 256 
  = 	
2 −  ×  =

/ 2 −  ×       (1) 257 
 258 
where  is the fraction of the drug released,  !  is amount of the drug initially loaded into 259 
the capsule, " is the surface area exposed to the release buffer,  is the diffusion coefficient of 260 
the drug,  is the solubility of the drug,  is the concentration of the drug initially inside the 261 
inner cavity (0.991 mol/L for nadolol and 1.15 mol/L for metoprolol), # is the total volume of 262 
the hydrogel formulation, and  is time. The solubilities in water (at 25 °C), for nadolol and 263 
metoprolol are 8330 and 402 mg/L (at 25 °C), respectiv ly. 264 
 265 
When the released fractions are then plotted against	√, the curves should be linear and the 266 
slopes (&) should be dependent on the area exposed to the release buffer divided by the total 267 
volume of the hydrogel. These plots are shown in Figure 4. The Eq. (1) can be further simplified 268 
to Eq. (2) by combining drug-dependent parameters variables to a constant ' (' =269 
/ 2 − (/	) and drug-independent design parameters to a constant ) () = "/#), 270 
which is related to the geometry of the capsules. 271 
 272 




  275 
Fig 4. Fitted Higuchi equations (lines) to the nadolol (A) and metoprolol (B) release data for all 276 
three capsule designs (Tube, Large, and Small). The data points are the same as in Figure 3 but 277 
only the part of the data with no evident drug degradation was used for the fitting. 278 
 279 
The slopes from Figure 4, and the corresponding values of the formulation parameters a are 280 
shown in Table 1. For metoprolol, only the parts of the release curves where no clear degradation 281 
of the drug was seen were used to do the theoretical fi s. It is worth noting that in an ideal case, 282 
the release rate would be completely controlled by the design parameter a, as ' was constant for 283 
each drug release series, however, a number of things such as swelling or more complex 284 
geometries can lead to deviations from the standard Higuchi equation. Any visible swelling 285 
could be ruled out based on visual observations of the capsules in buffer solutions before and 286 
after the measurements. However, an analysis of the ratios of the slopes to the ratios of ) will 287 
indicate how well the release curves fit the Higuchi equation and helps in verifying the release 288 




Table 1. Slopes from the release rate fitting in Figure 4 and  comparison of the design variables 291 
(a) indicating ideal release behavior to the slopes (k) of the real release rates. The parameters are 292 
normalized to those obtained for the tube-design. 293 
 294 
 295 
All the designs could be modeled with the Higuchi equation. Especially the release data from the 296 
tube-design shows excellent near-perfect fits to Eq. (1). The equation is theoretically derived for 297 
a case very much like our current design [34]. And although the release rate from the large 298 
bottleneck was slightly faster than expected, the ratio of the design parameters and the ratios of 299 
the slopes of the large and tube designs are close to each other (0.374 vs. 0.480 and 0.474), 300 
indicating similar release mechanism as in the case of the tube design. In the case of the small 301 
bottleneck, a larger deviation from theory was seen and the release rate was much faster than 302 
would have been expected (0.132 vs. 0.335). The reason is that the Higuchi equation only 303 
describes release from the neck of the capsule, i.e. from a system with constant cross-section to 304 
volume ratio. As the bottleneck is quite short, it is not able to control the release rate alone. At 305 
some point during the release experiment, the diffusion from the larger inner cavity to the neck 306 
part will start to dominate the release kinetics. In this area, the cross section to volume ratio of 307 
the large and small designs are similar. And that is why we see that the slopes of these two 308 
designs start approaching each other later in the release measurements. The jump to higher 309 
 Design 
parameter ratios 
& &/&*+,! R2 
 Metoprolol Nadolol Metoprolol Nadolol Metoprolol Nadolol 
Tube 
)/)*+,! 7.69 1.73 1.00 1.00 0.99 1.00 
1.00 
Large 
)/)*+,! 3.69 0.82 0.48 0.47 0.99 1.00 
0.37 
Small 




release fractions for the large design in the early stage of the release is due to the difference in 310 
the cross-section to volume ratios inside the neck of the capsule.  311 
 312 
As the release rates for several types of molecules has been measured for the same CNF hydrogel 313 
grade [18], we can estimate the release rates of various therapeutical molecules for our implant. 314 
In addition, the same CNF hydrogel grade has been proven to be freeze-dryable without the loss 315 
of rheological properties nor any changes in its release profile [18]. For subcutaneous 316 
implantation the thickness of the capsule walls could be decreased for increased comfort and 317 
patient compliance. Despite PLA being an excellent ma erial for the current in vitro tests, the 318 
material could be further enhanced to prevent foreign body reaction and bacterial growth. Recent 319 
breakthroughs include foreign body resistant materils [35]. To prevent biofilm formation in in 320 
vivo environment, antimicrobial material such as nitrofu antoin can be mixed with the PLA [36-321 
37]. In addition, the outer surface of the PLA capsule can be post-operated smoother to reduce 322 
surface area for biofilm formation [36]. 323 
 324 
4 Conclusions 325 
 326 
In summary, the obtained leakage tests and in vitro results from model compounds demonstrate 327 
the suitability of the CNF hydrogel filled 3D printed PLA capsules as sustained release platforms 328 
without the use of any additional excipients. The diameter of the capsules release channel 329 
(“bottleneck”) can be modified effortlessly resulting in several adjustable parameters together 330 
with the drug and hydrogel concentrations and a high control over the release rate. From the 331 
theoretical analysis of the results it can be concluded that the tube and the large designs can be 332 
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modeled by the Higuchi equation. As the neck is made thinner, internal diffusion kinetics 333 
become more complicated and deviations from theory are seen. Nevertheless, a control over the 334 
release rates was maintained and the behavior of all systems can be explained by the varying 335 
cross-section to volume ratios. As the capsules are injected with the hydrogel formulations post-336 
printing, the drug substances do not undergo heating, resulting in wide compatibility for 337 
therapeutic compounds such as proteins and liposomes. In the future, the actual injection of the 338 
hydrogel formulations could be performed automatically by 3D printers and an antimicrobial 339 
PLA feedstock could be implemented in the FDM printing.  340 
 341 
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